BSI-201 (Iniparib), a iodonitrobenzamide-based cytotoxic agent, was initially considered to be a PARP inhibitor based on its abillity to inactivate PARP by means of zinc ejection from the zinc finger of the enzyme. [1]Despite its ability to kill normal and neoplastic cells at high concentrations (>40 uM), further studies revealed that BSI-201 did not selectivly kill homologous-recombination (HR)-deficient cells, sensitize cells to topoisomerase I poisons, or inhibit PARP in situ, as seen with olaparib and veliparib. [2]Through a battery of enzymatic, cellular, and viability assays, BSI-201 was shown to nonselectively modify cysteine-containing proteins in tumor cells. It is also postulated that the formation of nonspecific adducts can alter stability, activity, and localization, thus inducing apoptosis, stress, cell-cycle perturbation, or DNA damage. [3]

Technical information:

Shipping Condition: The product is shipped in a glass vial at ambient temperature.Storage condition: For longer shelf life, store solid powder at 4^oC desiccated, or store DMSO solution at -20^oC.

Reference:

Other Information:

Product Specification (pdf) MSDS (pdf) Certificate of Analysis is available upon request.

Cellagen利用广泛的研究以及我们在干细胞生物学，药物化学和产品开发方面的专业知识，Cellagen长期以来一直为专业OEM产品提供世界领先的公司，为一线干细胞研究奠定了基础。

现在，Cellagen扩展了其最佳产品系列，并直接向研究界提供。Cellagen与世界领先的科学家有着密切的联系，并且始终认识到高标准科学研究的未满足需求。